October 15, 2018

TRASIS offers the widest range of PSMA tracers to be produced on the same synthesizer.

Düsseldorf, 15 October 2018.

Prostate cancer is the second leading cause of cancer death for men in many parts of the world. For imaging, PSMA-based radio tracers target the PSMA  (Prostate Specific Membrane Antigen) transmembrane glycoprotein, which is strongly upregulated in prostate cancer cells. In this way, the PET tracer provides important molecular information on cancer and metastases localization within the prostate.

AllinOne family versatility proven

Once again, with these 4 PSMA processes, the AllinOne family proves its versatility. Depending on your needs, your source of activity and your facilities, PSMA-based radio tracers can be produced on AllinOne, AllinOne mini or EASYONE modules. Even the latest developed compounds still fits on the All-in-one. No need to change the machine when you need a new compound!

 
AllinOne
AllinOne mini
EASYONE
[18F] PSMA 1007
   
[18F] PSMA 7
   
[18F] DCFPyL
   
[18F] PSMA HBED

 

Fully automated processes and ready-to-use consumables for less exposure

The operator places the cassette, plugs the reagents, performs the actions as instructed by the user interface and then launches the synthesis. Kits are supplied to be used without extra lab bench preparation.  At the end of the synthesis, the process includes a cassette rinsing that eliminates most of the residual activity. The operator can safely remove the kit and prepare the module for the next production.

 
Radiochemistry
Purity
Synthesis time
Typical production yield
[18F] PSMA 1007
≥ 98%
40 min
40 ± 5% Non-decay corrected
[18F] PSMA 7
≥ 95%
60 min
30 ± 5% Non-decay corrected
[18F] DCFPyL
≥ 95%
60 min
30 - 35% Non-decay corrected
[18F] PSMA HBED
≥ 98%
16 min
60-80% Non-decay corrected



IMG_20181015_144409_0.jpg